Comparing Cellectis (NASDAQ:CLLS) & Amylyx Pharmaceuticals (NASDAQ:AMLX)

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Cellectis (NASDAQ:CLLS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, dividends and risk.

Profitability

This table compares Amylyx Pharmaceuticals and Cellectis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Cellectis	-102.34%	-94.19%	-21.34%

Valuation and Earnings

This table compares Amylyx Pharmaceuticals and Cellectis”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37 million	37.49	-$144.74 million	($1.43)	-20.56
Cellectis	$56.58 million	2.08	-$67.59 million	($0.65)	-1.80

Cellectis has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Amylyx Pharmaceuticals has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.21, meaning that its stock price is 221% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Amylyx Pharmaceuticals and Cellectis, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1	0	7	1	2.89
Cellectis	2	2	2	1	2.29

Amylyx Pharmaceuticals currently has a consensus target price of $40.71, indicating a potential upside of 38.48%. Cellectis has a consensus target price of $5.46, indicating a potential upside of 366.67%. Given Cellectis’ higher possible upside, analysts plainly believe Cellectis is more favorable than Amylyx Pharmaceuticals.

Insider & Institutional Ownership

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Amylyx Pharmaceuticals beats Cellectis on 7 of the 13 factors compared between the two stocks.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.